van Boxtel W et al. |
Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. |
2017 |
Oral Oncol. |
pmid:28673692
|
Riechelmann H et al. |
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. |
2008 |
Oral Oncol. |
pmid:18203652
|
Wang L et al. |
Formal total synthesis of N-methylmaysenine. |
2009 |
Org. Lett. |
pmid:19296671
|
Meyer A et al. |
Chemoenzymatic approaches toward dechloroansamitocin P-3. |
2007 |
Org. Lett. |
pmid:17378571
|
Frenzel T et al. |
Synthesis of the N-acetylcysteamine thioester of seco-proansamitocin. |
2006 |
Org. Lett. |
pmid:16381586
|
Mancuso L et al. |
Bioreduction of aryl azides during mutasynthesis of new ansamitocins. |
2013 |
Org. Lett. |
pmid:23981134
|
Wood AC et al. |
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. |
2013 |
Pediatr Blood Cancer |
pmid:23798344
|
Lai KC et al. |
Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay. |
2015 |
Pharm. Res. |
pmid:25630819
|
Squires H et al. |
Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. |
2016 |
Pharmacoeconomics |
pmid:26892972
|
Hamel E |
Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. |
1992 |
Pharmacol. Ther. |
pmid:1287674
|